Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tetrahydrocannabivarin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Incannex Healthcare
Deal Size : Undisclosed
Deal Type : Acquisition
Incannex to Acquire APIRx Pharmaceuticals USA, LLC
Details : A focus of the combined APIRx and Incannex group will be the ongoing development of APIRx's CheWell, CanQuit and CanQuit-O cannabinoid combination MCGs to treat cannabis addiction, nicotine addiction and opioid addiction.
Brand Name : CheWell
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 24, 2022
Lead Product(s) : Tetrahydrocannabivarin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Incannex Healthcare
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?